Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples

Gary W. Moore BSc, DBMS1 | James C. Maloney BSc (Hons)1 | Naomi de Jager MSc1 |
Clare L. Dunsmore MSc1 | Dervilla K. Gorman MSc (Ulster), MSc (South Bank)1 |
Richard F. Polgrean BSc1 | Maria L. Bertolaccini MD, PhD2

Abstract

Background: Gold standard lupus anticoagulant (LA) assays and reference plasmas do not exist and detection is based on inference in a medley of coagulation assays, creating potential for interpretive discrepancies when applying different algorithms.

Objectives: To investigate discrepancies from applying different algorithms to a common data set.

Methods: Diagnostic data on 311 non-anticoagulated patients LA-positive by dilute Russell’s viper venom time (dRVVT) and/or dilute activated partial thromboplastin time (dAPTT) assays were employed to compare algorithms. Routine testing applied interpretive criteria from guidelines endorsing classification as LA-positive despite negative mixing tests, after exclusion of other clotting abnormalities. Integrated testing without mixing tests, and the classical algorithm where negative mixing tests preclude confirm tests, were then retrospectively applied to those data.

Results: Initial testing showed 92/311 (29.6%) were LA-positive by dRVVT only, 156/311 (50.1%) by dAPTT only, and 63/311 (20.3%) by both assays. All dAPTT-positive plasmas remained positive with integrated testing but eight dRVVT-positives became negative. Other data suggested they were false-negatives. The classical algorithm altered 52/155 (33.5%) dRVVT and 111/219 (50.7%) dAPTT interpretations to LA-negative because of normal mixing tests, most of which were apparently weak LA in undiluted plasma.

Conclusions: The classical algorithm improves diagnostic specificity and confidence but risks missing some genuine LA due to false-negative mixing tests. Integrated testing can be diagnostically accurate and logistically efficient but oversimplifies complex cases. Performing mix and confirm in response to an elevated screen with their interpretation based on clinical data, coagulation screens and the LA-assay design offers a potentially valuable option.
Antiphospholipid syndrome (APS) is diagnosed in patients with vascular thrombosis or pregnancy morbidity whose laboratory assays demonstrate persistent antiphospholipid antibodies (aPL). Since thrombosis and pregnancy morbidity are non-specific for APS, the diagnosis is reliant on accurate and robust aPL detection. Two of the criteria antibodies, anticardiolipin antibodies (aCL) and anti-IIb-β3-glycoprotein I antibodies (aIIbGPI), are detected in semi-quantitative solid-phase assays, whilst lupus anticoagulants (LA) are detected by inference based on antibody behaviour in a medley of phospholipid-dependent coagulation assays.

No single coagulation test is sensitive for all LA and two test systems of differing analytical principles are needed to maximise detection rates. All current guidelines recommend that dilute Russell’s viper venom time (dRVVT) must be one of these tests, mainly for specificity in detecting clinically significant LA, normally partnered with LA-responsive activated partial thromboplastin time (APTT). Classically, the medley for each test type comprises an initial screening test on undiluted plasma, which if elevated is followed by a mixing test to evidence inhibition, which if also elevated, is followed by a confirmatory test on undiluted plasma to demonstrate phospholipid dependence.

Debate has ensued in recent years concerning the place of mixing tests in LA detection. Some contend that assaying screen and confirm tests and immediately assessing for phospholipid dependence, so-called integrated testing, will detect LA in most cases, even where other causes of elevated clotting times are present. Others indicate that situations such as possible or known presence of other causes of elevated clotting times, potent antibodies and the “lupus cofactor effect,” mean that mixing tests are crucial to accurate data interpretation and improved specificity. Either way, it is widely acknowledged that the dilution factor can make weaker LAs appear negative despite clear positivity from screen and confirm results in undiluted plasma.

Current guidelines from the International Society on Thrombosis and Haemostasis (ISTH) and British Society for Haematology (BSH) endorse the classical algorithm. However, the BSH guidelines state that in the absence of other causes of prolonged clotting times, samples with negative mixing tests but positive screen and confirm results in undiluted plasma can be classified as LA positive. This implies that all three tests are performed and then interpreted in light of assay design instead of using mixing test results as a diagnostic decision point. The Clinical and Laboratory Standards Institute (CLSI) guideline reprioritizes test order to screen-confirm-mix, recommending that the mixing test is initiated only when screen and confirm analysis is not clear-cut and/or when other causes of prolonged clotting times are known or suspected. The present study retrospectively assesses diagnostic data from 311 plasma samples from non-anticoagulated patients deemed LA-positive according to the BSH guideline, and by extension the CLSI guideline, by subsequently applying interpretations based on integrated testing, and the classical algorithm.

1 INTRODUCTION

2 MATERIALS AND METHODS

2.1 Blood collection, manipulation, and storage

Blood was collected into Vacuette tubes (Greiner Bio-One Ltd, Stonehouse, UK) containing a one-tenth volume of 0.105 mol L⁻¹ (3.2%) tri-sodium citrate and double centrifuged to obtain platelet poor plasma (PPP) which was stored at −80°C until use.

2.2 Lupus anticoagulant assays

Routine dRVVT was performed with Life Diagnostics (LD) LA Screen and LA Confirm reagents (Diagnostica Stago UK, Theale, UK). Dilute APTT (dAPTT) employed Stago PTT-LA (Diagnostica Stago) in the screen and addition of Bio/Data Corporation LA Confirmation Reagent (Alpha Labs, Eastleigh, UK) for the confirm. All elevated screens received the confirm test plus screen and confirm on 1:1 mixing studies with normal plasma. CRYOcheck™ Normal Reference Plasma (Alpha Labs) was used for 1:1 mixing tests. The LA assays were performed on a Sysmex CS2000i analyser (Sysmex UK, Milton Keynes, UK). Screen and confirm clotting times were converted to normalized ratios via their reference interval (RI) mean clotting times. Results were defined as consistent with the presence of a LA if the screen ratio was greater than the RI upper limit with ≥10% correction by the confirm ratio, which had been previously locally validated. Mixing tests with screen and confirm assays were performed for
dRVVT and dAPTT to increase specificity, particularly where confirm ratios were themselves elevated. In view of potential differences between normal pooled plasma (NPP) and RI mean clotting times, mixing test ratios were derived from NPP results as denominator so that the ratios reflected the effect of index plasmas on the NPP in which they were mixed.

The RIs, and thus cut-offs, had previously been locally derived from 43 normal donor plasmas. All had Gaussian distributions and were calculated as ±2 standard deviations (SD) of the mean. The ISTH recommendation of 99th percentile cut-offs was not applied as it has proven controversial, and lower cut-offs have been shown to allow better detection rates.

### 2.3 | Coagulation screening tests

Coagulation screening was performed to exclude factor deficiencies and undisclosed anticoagulation. Prothrombin time, APTT, thrombin time, and Clauss fibrinogen were performed on a Sysmex CS2100i analyser (Sysmex UK) using Dade Innovin recombinant thromboplastin, Actin FS, Thromboclotin and Thrombin-Reagent (Siemens Healthcare, Marburg, Germany) respectively. Actin FS was employed as it is a LA-unresponsive routine APTT reagent and suited to exclusion of other causes of elevated clotting times.

### 2.4 | Patients

Diagnostic data from routine LA testing at Guy’s and St. Thomas’ Hospitals for 311 non-anticoagulated patients interpreted as LA-positive by following the BSH/CLSI algorithms were re-evaluated by applying integrated testing alone to screen and confirm results from undiluted plasma, and also the classical algorithm where an elevated screen but negative mixing test precludes performance of a confirm test and allows classification of the sample as being LA-negative. The ratio generated from integrated testing was derived from screen ratio/confirm ratio and not from raw clotting times because clotting times for the paired screen and confirm reagents with NPP differed for both dRVVT and dAPTT. Schematics of the algorithms are shown in Figure 1.

One hundred and six of the patients had antiphospholipid syndrome (APS), 35 had systemic lupus erythematosus (SLE) and persistent LA, 26 had SLE and first LA-positive testing, and 144 were clinically appropriate patients being investigated for APS. Seventy of the 106 (66%) APS patients also had elevated aCL and/or a β2GPI.

### 3 | RESULTS AND DISCUSSION

The lack of gold standard assays and reference plasmas continues to hamper standardisation of LA detection. Instead, diagnostic...
practitioners aim to employ reagents recognised as LA-sensitive and make choices on suitable algorithms based on published guidelines, personal experience, manufacturer recommendations, and/or logistical and cost considerations.\textsuperscript{26,27} The classical algorithm has been questioned in recent years due to concerns on false-negative mixing tests arising from the dilution effect,\textsuperscript{2,4,5,7-10,15} but also to the increasing adoption of integrated testing that circumvents traditional testing order and allegedly detects LA without mixing tests.\textsuperscript{2,8-11,17} Recent reports investigating the effect of excluding mixing tests have shown interpretation discordance between the integrated and classical algorithms but these studies concentrated only on the use of dRVVT.\textsuperscript{6,13}

We present a study on 311 samples interpreted as being LA-positive via a BSH/CLSI directed approach. These results are herewith reinterpreted with integrated testing and the classical algorithm applied to dRVVT and dAPTT.

From the routine testing and application of BSH/CLSI algorithms, 92/311 (29.6%) were LA-positive by dRVVT only, 156/311 (50.1%) by dAPTT only, and 63/311 (20.3%) in both dRVVT and dAPTT. Diagnostic data are summarised in Table 1. Because patients were not anticoagulated and routine APTT was LA-insensitive, these samples could be designated as LA-positive when mixing tests were negative.\textsuperscript{4,5} The ISTH guideline acknowledges that confirm tests in LA-positive samples do not always return into the reference range and the CLSI algorithm indicates that apparently LA-positive samples showing elevated confirm ratios should undergo mixing tests to increase specificity by excluding factor deficiencies and most anticoagulation.\textsuperscript{2,5,6,13} Twenty of 311 (6.4%) had mildly elevated routine APTT ratios (range 1.3-1.5, mean/median 1.34/1.30, cut-off 1.2). All were LA-positive by dAPTT testing (screen ratio range 1.22-3.19, mean/median 1.62/1.45), 12 of which were also dRVVT testing-positive. The mild elevations were considered to be due to the LA and not undisclosed anticoagulation. Two each had INR of 1.3 (cut-off 1.2) but were dRVVT testing-positive (screen ratios 2.26/1.66) and dAPTT testing-positive (screen ratios 1.88/1.35), and were also considered due to the LAs.

Thirty four of 155 (21.9%) dRVVT-positive samples had confirmatory test ratios above the cut-off of 1.10, (range 1.11-1.87, mean 1.21, median, 1.16), 4 of which had negative mixing tests. All 4 had normal routine APTT and one was also dAPTT-positive, and in the absence of evidence for other causes of elevated clotting times, were considered genuine LA-positive.\textsuperscript{2,4} Seventeen of 34 were also dAPTT-positive. Twenty of 219 (9.1%) dAPTT-positive samples had confirmatory test ratios above the cut-off of 1.18, (range 1.19-1.54, mean 1.26, median, 1.22), 5 of which also had mildly elevated routine APTT ratios of 1.3 -1.4, broadly concordant with their dAPTT confirmatory test ratios (range 1.21-1.54). Two of 20 had negative mixing tests. Their confirmatory test ratios were 1.26 and 1.21 and both had routine APTT ratios of 1.4 (cut-off 1.2), yet they achieved 21.7% and 16.6% correction and were consequently considered LA-positive.\textsuperscript{4}

Twelve of 20 were also dRVVT-positive. Devreeze\textsuperscript{6} and Devreese and De Laat\textsuperscript{13} reported a higher prevalence of dRVVT-positive samples with elevated confirm results yet the majority were in patients on vitamin K antagonists. Our study was specifically performed on non-anticoagulated patients to assess interpretation discordances in otherwise uncompromised plasma samples. Such patients could have a LA capable of overcoming some of the overwhelming effect of high concentration phospholipid confirm reagents,\textsuperscript{2,6,12} a co-existing factor deficiency,\textsuperscript{2,6} or in the case of APTT testing, a clinically insignificant contact factor deficiency.\textsuperscript{28}

Generating the integrated testing ratio from screen and confirm ratios in undiluted plasma and interpreting elevated integrated ratios as LA-positive irrespective of mixing test results altered 8/155 (5.2%) of dRVVT interpretations to LA-negative (Table 2). Four of those were dAPTT-positive, one of which also had elevated aCL and α2GPI, two had elevated mixing tests, one of which had had elevated aCL and α2GPI, and the other 2 had established, persistent LA. Their dRVVT screen ratios ranged from 1.18-1.29, mean 1.23, median 1.23. Thus, they were all likely false-negatives arising from differences in sensitivity between the percent correction and integrated ratio cut-offs. The 10% correction value has been advocated by BSH guidelines since 1991\textsuperscript{4,18,29} and had been locally validated for dRVVT and dAPTT from reference range data.\textsuperscript{3} All dAPTT interpretations remained LA-positive with integrated testing.

One omission from our study is integrated testing on samples deemed LA-negative from BSH/CLSI or classical algorithms because dRVVT and dAPTT screen ratios were within reference ranges. Whilst it can be reasonably argued that normal screen ratios do not fulfill one of the crucial diagnostic criteria, being elevation of a phospholipid-dependent screening test, a converse view exists suggesting that screen and confirm discordance will detect weaker LA that prolong screen clotting times above a patient-specific baseline but not beyond the cut-off of from a population distribution.\textsuperscript{2,8,30} A separate debate exists on the significance of apparently weaker LA but the purpose of

| TABLE 1 | Diagnostic data on 311 plasma samples positive for lupus anticoagulant by dRVVT and/or dAPTT analysis according to BSH and CLSI recommended algorithms |
| --- | --- | --- | --- | --- |
| **Assay** | **n** | **Screen ratio** | **Percent correction of screen ratio by confirm ratio** | **Positive in mixing test** |
| | | **Cut-off** | **Range** | **mean** | **median** | **Range** | **mean** | **median** | **n (%)** |
| dRVVT | 155 | >1.17 | 1.18-3.12 | 1.45 | 1.31 | 10.2-64.7 | 24.2 | 20.8 | 103 (66.5) |
| dAPTT | 219 | >1.20 | 1.21-4.49 | 1.45 | 1.33 | 10.2-72.9 | 26.1 | 24.1 | 108 (49.3) |

BSH, British Society for Haematology; CLSI, Clinical and Laboratory Standards Institute; dAPTT, dilute activated partial thromboplastin time; dRVVT, dilute Russell’s viper venom time.
### TABLE 2  Diagnostic data on eight plasma samples negative for lupus anticoagulant by dRVVT integrated testing

| Clinical details                  | dRVVT screening test ratio (CO >1.17) | dRVVT confirm test ratio (CO >1.10) | dRVVT integrated test ratio (CO >1.13) | dRVVT percent correction (CO >10%) | dRVVT mixing test ratio (CO >1.13) | dAPTT   | aCL       | aβ2GPI    |
|----------------------------------|---------------------------------------|-------------------------------------|----------------------------------------|-----------------------------------|-----------------------------------|---------|-----------|-----------|
| APS                              | 1.23                                  | 1.09                                | 1.13                                   | 11.4                              | 1.14                              | Positive| Elevated  | Elevated  |
| CTD, first LA testing            | 1.29                                  | 1.15                                | 1.12                                   | 10.9                              | 1.17                              | Negative| Elevated  | Elevated  |
| SLE with persistent LA           | 1.18                                  | 1.06                                | 1.11                                   | 10.2                              | 1.02                              | Positive| Normal    | Not done  |
| ? APS, first LA testing          | 1.21                                  | 1.07                                | 1.13                                   | 11.6                              | 1.20                              | Negative| Not done  | Not done  |
| APS                              | 1.19                                  | 1.05                                | 1.13                                   | 11.8                              | 1.12                              | Positive| Normal    | Normal    |
| SLE with persistent LA           | 1.22                                  | 1.08                                | 1.13                                   | 11.5                              | 1.11                              | Negative| Normal    | Normal    |
| APS                              | 1.23                                  | 1.10                                | 1.12                                   | 10.6                              | 1.12                              | Negative| Normal    | Normal    |
| Thrombocytopenia, first LA testing | 1.28                              | 1.15                                | 1.11                                   | 10.2                              | 1.20                              | Positive| Normal    | Not done  |

aβ2GPI, anti-β2-glycoprotein I antibodies; aCL, anticardiolipin antibodies; APS, antiphospholipid syndrome; CTD, connective tissue disease; CO, cut-off; dAPTT, dilute activated partial thromboplastin time; dRVVT, dilute Russell’s viper venom time; LA, lupus anticoagulant.

### TABLE 3  Interpretive outcomes from classical algorithm of 311 plasma samples positive for lupus anticoagulant by dRVVT and/or dAPTT analysis according to BSH and CLSI recommended algorithms

| Assay and classical algorithm interpretation | n   | Screen ratio | Mean/median | Percent correction | Mean/median | Integrated test ratio | Mean/median | Mixing test ratio | Mean/median |
|---------------------------------------------|-----|--------------|-------------|--------------------|-------------|-----------------------|-------------|-------------------|-------------|
| dRVVT positive                              | 103 | 1.20-3.12    | 1.55/1.38   | 10.2-64.7          | 27.8/25.0   | 1.11-2.83             | 1.44/1.33   | 1.14-2.57         | 1.41/1.26   |
| dRVVT negative                              | 52   | 1.18-1.44    | 1.26/1.25   | 10.2-28.7          | 17.2/16.0   | 1.11-1.40             | 1.21/1.19   | 0.91-1.13         | 1.10/1.11   |
| dAPTT positive                              | 108  | 1.21-4.49    | 1.58/1.40   | 10.2-72.9          | 27.1/23.9   | 1.11-3.69             | 1.44/1.31   | 1.16-3.33         | 1.48/1.28   |
| dAPTT negative                              | 111  | 1.21-1.68    | 1.33/1.29   | 10.2-44.1          | 25.1/25.4   | 1.11-1.79             | 1.35/1.34   | 0.93-1.15         | 1.10/1.10   |

Cut-offs for dRVVT screen ratio, percent correction, integrated ratio and mixing ratio respectively were 1.17, 10.0, 1.13, 1.13, and for dAPTT, 1.20, 10.0, 1.10, 1.15. Of the 52 dRVVT mixing test negative samples, 20 were from patients with APS, seven were from patients with SLE (three of which had persistent LA), and the majority of the remainder were being tested in response to thrombosis or recurrent miscarriage; 22 of 52 (42.3%) had elevated aCL and/or aβ2GPI. Of the 111 dAPTT mixing test negative samples, 25 were from patients with APS, 26 were from patients with SLE (six of which had persistent LA), four were in response to an elevated routine APTT, and the majority of the remainder were being tested in response to thrombosis or recurrent miscarriage; 40 of 111 (36.0%) had elevated aCL and/or aβ2GPI, aβ2GPI, anti-aβ2GPI antibodies; aCL, anticardiolipin antibodies; APS, antiphospholipid syndrome; BSH, British Society for Haematology; CLSI, Clinical and Laboratory Standards Institute; dAPTT, dilute activated partial thromboplastin time; dRVVT, dilute Russell’s viper venom time.
the present study was to evaluate differences in samples fulfilling the standard elevated screening test criterion.

ISTH and CLSI Guidelines recommend interpreting mixing tests with a mixing test-specific cut-off (MTC) or calculation of the index of circulating anticoagulant (ICA). Recent reports suggest that MTC achieves higher detection rates. Employing a locally derived MTC in this study maximised mixing test detection of LA. Yet, test ratios were below cut-offs. Similar frequencies of false-negative mixing test results have been previously reported and external quality assessment schemes have reported false-negative mixing test results as a common cause of misclassification of weaker LA. More specific assays have been reported to be less affected, which is mirrored in the data for this study where dRVVT was less affected by false-negative mixing tests than dAPTT. Comparative data between LA-positive and LA-negative samples via this algorithm are given in Table 3. The dilution effect is an accepted phenomenon and therefore our routine LA detection strategy does not adopt mixing test values as a decision point but responds to all elevated screens with confirm and mixing tests and interprets accordingly. The data suggest that stronger antibodies, as implied by degree of screening test elevation, are more likely to elevate mixing test ratios than weaker antibodies (those with lower screen ratios) and prompt confirmatory test performance in the classical algorithm. However, there was some degree of cross-over with some samples whose screen ratios in undiluted plasma were close to cut-offs nonetheless elevating mixing tests, whilst some others with moderately elevated screen ratios (dRVVT up to 1.44, dAPTT up to 1.68) did not. Manifestation in mixing tests seems to be a function of more than just potency, other possible contributory factors include epitope specificity, antibody avidity, and reagent composition. 

In summary, the number of samples classified as LA-positive differed depending on the method of interpretation, particularly in the case of the classical algorithm where a design limitation of mixing tests precluded completion of the assay medley that could otherwise reveal an LA. The discrepancies occurred mainly with samples whose screen ratios were slightly, and occasionally moderately, elevated, a common area of between-center discordance in external quality assurance challenges. The absence of reference plasmas and gold standard assays means that we cannot be certain which of these arguably ambiguous result sets reflect genuine LA and those with positive mixing tests can engender increased confidence in specificity. A major contributor to between-department discrepancies with lower titer antibodies irrespective of the algorithm employed is cut-off generation. It is widely accepted, and recommended in all guidelines, that cut-offs must be locally derived yet laboratories vary in their approach to this issue and some laboratories continue to adopt manufacturers’ generic cut-offs. Conversely, no assay is perfect and the dilution effect is a genuine confounder, so performing mix and confirm tests in response to an elevated screen coupled with informed interpretation based on clinical data, routine coagulation screening tests and LA-assay design offers us a potentially valuable interpretive middle ground.

**REFERENCES**

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.
2. Moore GW. Recent guidelines and recommendations for laboratory detection of lupus anticoagulants. Semin Thromb Hemost 2014;40:163–71.
3. Pendo V, Tripodi A, Reber G, et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009;7:1737–40.
4. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47–58.
5. CLSI. Laboratory testing for the lupus anticoagulant; approved guideline. CLSI document H60-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014.
6. Devrees KM. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants? J Thromb Haemost 2010;8:1120–2.
7. Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012;38:385–9.
8. Reber G, Meijer P. In ECAT veritas? Lupus. 2012;21:722–4.
9. Hong SK, Hwang SM, Kim JE, Kim HK. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems. Blood Coagul Fibrinolysis 2012;23:739–44.
10. Pennings MT, De Groot PG, Meijers JC, Huisman MA, Derksen RH, Urbanus RT. Optimisation of lupus anticoagulant tests: should test samples always be mixed with normal plasma? Thromb Haemost 2014;112:736–42.
11. Aboud M, Morel-Kopp MC, Ward C, Coyle L. False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant. J Thromb Haemost 2010;8:2070–3.
12. Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010;8:2828–31.
13. Devrees KM, De Laat B. Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J Thromb Haemost 2015;13:1475–8.
14. Devrees KM. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants. Thromb Res 2007;119:369–76.
15. Moore GW, Savidge GF. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied. Thromb Res 2006;118:523–8.
16. Moore GW, Brown KL, Bromidge ES, Drew AJ, Ledford-Kraemer MR. Lupus anticoagulant detection: out of control? Int J Lab Haematol. 2013;35:128–36.
17. McGlasson DL, Fritsma GA. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits. Semin Thromb Hemost 2013;39:315–9.
18. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000;109:704–15.
19. Lawrie AS, Mackie IJ, Purdy G, Machin SJ. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999;81:758–62.
20. Moore GW, Culhane AP, Daw CR, Noronha CP, Kumano O. Mixing test specific cut-off is more sensitive at detecting lupus anticoagulant than index of circulating anticoagulant. Thromb Res 2016;139:98–101.
21. Depreter B, Devreese KM. Differences in lupus anticoagulant final conclusion through clotting time or Rosner index for mixing test interpretation. Clin Chem Lab Med 2016;54:1511–6.
22. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline—Third Edition. CLSI document C28-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
23. Gerbutavicius R, Fareed J, Messmore HL Jr, et al. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell’s viper venom tests revisited. Clin Appl Thromb Hemost 2002;8:115–24.
24. Tripodi A, Chantarangkul V, Cini M, et al. Variability of cut-off values for the detection of lupus anticoagulants: results of an international multicenter multiplatform study. J Thromb Haemost 2017;15:1180–90.
25. Fritsma GA, Dembitzer FR, Randhawa A, et al. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. Am J Clin Pathol 2012;137:904–8.
26. Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by North American clinical laboratories. Am J Clin Pathol 2010;134:764–73.
27. Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories? J Thromb Haemost 2011;9:2117–9.
28. Moore GW, Sangle SR, Archer RA, Maloney JC, Rahman A, D’Cruz DP. Complete prekallikrein deficiency masquerading as a lupus anticoagulant. Thromb Res 2014;133:301–2.
29. Machin SJ, Giddings JC, Greaves M, et al. Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1991;44:885–9.
30. Jacobsen EM, Wisløff F. False negative screening tests for lupus anticoagulants—an unrecognized problem? Thromb Res 1999;82:445–51.
31. Kumano O, Moore GW. Mixing test specific cut-off is more sensitive at detecting in vitro lupus anticoagulant inhibition than index of circulating anticoagulant with multiple APTT and DRVVT reagents. J Thromb Haemost 2016;14(Suppl 1):85. Abstract number LUP03.

How to cite this article: Moore GW, Maloney JC, de Jager N, et al. Application of different lupus anticoagulant diagnostic algorithms to the same assay data leads to interpretive discrepancies in some samples. Res Pract Thromb Haemost. 2017;1:62–68. https://doi.org/10.1002/rth2.12006